Several HESI programs will be featured throughout the meeting.
Environmental Mutagenesis & Genomics Society 54th Annual Meeting
September 9, 2023 – September 13, 2023
Chicago, IL, USA
CT-TRACS committee is an international network of experts from multiple sectors (public and private sector research scientists, regulators, cell therapy developers, clinicians, imaging experts, and enabling tool developers) who work collaboratively sharing knowledge, experience, and resources to secure the safety of cell-based therapies.
To facilitate the translation of cell-based therapies to the clinic by driving the development of tools, methods and knowledge required to evaluate safety and fate of therapeutic cells.
HESI CT-TRACS is proud to be a partner in NC3Rs 2022 CRACK-IT challenge “T-ALERT: Animal-free tumourigenicity assessment of CAR-T and other genetically modified T cells”. CRACK-IT challenges provides UK and EU-based academics and SMEs with the opportunity to apply to develop new 3Rs tools, technologies or approaches and engage with new partners. The T-ALERT Challenge aims to develop an in vitro assay that can reliably evaluate tumourigenicity of human-engineered T cell therapies with the potential to be applied to multiple immune cell types.
As a partner, HESI and the CT-TRACS committee will help to create productive relationship between the challenge awardees and organisations that have expertise, data, or other resources that could support successful Challenge dissemination of the resulting technology. The HESI CT-TRACS Tumorigenicity Working Group will leverage its successful track record of multi-laboratory evaluation of relevant methods and assays in support of tumorigenicity evaluation of cell therapy products in support of the challenge winners.
This working group aims to identify current approaches, gaps, and needs in monitoring/evaluating the fate and activity of cells after their administration in vivo, to assess the safety of cell-based therapies.
This working group aims to address concerns regarding the potential for tumorigenicity of PSC-derived products by assessing and/or developing methodologies and approaches that could support tumorigenicity evaluation.
HESI’s Cell Therapy – TRAcking, Circulation, & Safety committee Biodistribution working group is launching an initiative to identify current approaches, gaps, and needs in monitoring/evaluating the fate and activity of cells after their administration in vivo, to assess the safety of cell-based therapies. As a result, we are reaching out to the broader scientific community, in Advanced Therapies, Regenerative Medicine and/or Imaging fields, to gather your valuable feedback.
Please help us gather important stakeholder input in this innovative and critical area by completing this short survey by 31 May 2024. Completion time is estimated at 10 min.
The outcome will be published in the peer-review literature to benefit the broader community.
Senior Advisor, Center for Patient and Consumer Safety (CPCS)
lmouries@hesiglobal.orgMedicines Evaluation Board, The Netherlands
AstraZeneca
September 9, 2023 – September 13, 2023
Chicago, IL, USA
Several HESI programs will be featured throughout the meeting.
June 1, 2023
Paris, France
Dr. Mick Fellows, co-chair of the CT-TRACS Committee was invited to speak about the developments of the committee project on advanced sequencing methods for detection of off-target edits in genome editing, a project that received support from HESI EIC via its “Foresight Proposal” award.
March 19, 2023 – March 23, 2023
Nashville, TN, USA
A number of HESI committees will have presentations and posters at the Society of Toxicology Meeting in Nashville, TN.
STEM CELLS Translational Medicine, 2024
This study addresses a critical safety concern in regenerative medicine—the presence of residual undifferentiated pluripotent stem cells (PSCs) in cell therapy products (CTPs), which poses a risk of tumor formation.
Regenerative Medicine, 2023
HESI’s Cell Therapy-TRAcking, Circulation & Safety Technical Committee completed an international, multisite study to evaluate the sensitivity and reproducibility of the highly efficient culture (HEC) assay, an in vitro assay to detect residual undifferentiated human pluripotent stem cells (hPSCs) in cell therapy ...
Cytotherapy, 2021
Cell-based therapies have been making great advances toward clinical reality. Despite the increase in trial activity, few therapies have successfully navigated late-phase clinical trials and received market authorization. One possible explanation for this is that additional tools and technologies to enable their ...
Cytotherapy, 2019
Pluripotent stem cells offer the potential for an unlimited source for cell therapy products. However, there is concern regarding the tumorigenicity of these products in humans, mainly due to the possible unintended contamination of undifferentiated cells or transformed cells. Here, we critically review currently available ...
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.